Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc.（BLCM）股票概览
关键指标与盈利、估值、营收、股息等标签页深链。
FMP · BLCM · 截至 Jun 9, 2026
关键指标
探索 Bellicum Pharmaceuticals, Inc. 数据
blcm stock data · financials财务快照
完整财报分析师评级与目标价
完整预测合计: 9 · 买入占比: 88.9%
竞争对手与同行
blcm competitorsBLCM
ACOR
BIOL
IMPL
INFIQ
NMTRQ股票表现
完整历史关于 Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat …
what is bellicum pharmaceuticals, inc. · blcm stock overview · bellicum pharmaceuticals, inc. company profile · who is bellicum pharmaceuticals, inc. ceo · blcm NASDAQ · bellicum pharmaceuticals, inc. headquarters · bellicum pharmaceuticals, inc. business segments
关于股票概览与关键数据
Bellicum Pharmaceuticals, Inc.（BLCM）是 Biotechnology 行业的 Healthcare 类公司，于 Dec 18, 2014 在 NASDAQ 上市。截至最近交易日，BLCM 股价为 $0.07，市值约为 $778,326。过去12个月累计回报 -76.64%，年初至今回报 -50.82%。
根据 9 位华尔街分析师，Bellicum Pharmaceuticals, Inc. 股票共识评级为Buy，12个月平均目标价为 $—。2022 财年 Bellicum Pharmaceuticals, Inc. 营收 $1.5M，净利润 -$25.0M。更多数据（营收历史、盈利、股息、市盈率）请使用上方标签页。
常见问题
截至最近一个交易日，Bellicum Pharmaceuticals, Inc.（BLCM）股价为 $0.07，在 NASDAQ 上市，52周区间为 $0.06 – $1.31。